Cantor Fitzgerald Issues Positive Estimate for ADCT Earnings

ADC Therapeutics SA (NYSE:ADCT) – Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for ADC Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($1.73) per share for the year, up from their prior forecast of ($1.91). The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share. Cantor Fitzgerald also issued estimates for ADC Therapeutics’ FY2026 earnings at ($1.97) EPS.

ADC Therapeutics (NYSE:ADCT) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.14). The company had revenue of $18.84 million during the quarter, compared to the consensus estimate of $17.82 million.

Several other equities analysts have also issued reports on the company. Wall Street Zen lowered ADC Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Guggenheim reiterated a “buy” rating and set a $10.00 price target on shares of ADC Therapeutics in a research note on Wednesday. Finally, Royal Bank Of Canada raised shares of ADC Therapeutics from an “outperform” rating to a “moderate buy” rating and lowered their price objective for the company from $8.00 to $5.00 in a research note on Friday, June 20th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, ADC Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.75.

ADC Therapeutics Price Performance

NYSE ADCT opened at $3.14 on Friday. The firm’s 50-day moving average is $3.02 and its two-hundred day moving average is $2.16. ADC Therapeutics has a 12 month low of $1.05 and a 12 month high of $3.97. The stock has a market capitalization of $353.25 million, a P/E ratio of -2.00 and a beta of 1.92.

Hedge Funds Weigh In On ADC Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC increased its stake in ADC Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 22,901 shares of the company’s stock valued at $46,000 after buying an additional 7,535 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of ADC Therapeutics by 21.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,520 shares of the company’s stock valued at $93,000 after acquiring an additional 8,246 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of ADC Therapeutics by 122.6% during the fourth quarter. Russell Investments Group Ltd. now owns 16,794 shares of the company’s stock worth $33,000 after acquiring an additional 9,248 shares during the period. Geode Capital Management LLC increased its stake in shares of ADC Therapeutics by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 963,109 shares of the company’s stock worth $1,917,000 after acquiring an additional 9,938 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in ADC Therapeutics by 39.4% during the fourth quarter. Wells Fargo & Company MN now owns 41,832 shares of the company’s stock worth $83,000 after purchasing an additional 11,834 shares in the last quarter. Hedge funds and other institutional investors own 41.10% of the company’s stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.